KYPROLIS

Kyprolis (carfilzomib) is a proteasome inhibitor used for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone.

Kyprolis is approved as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Recommended Dosage: 

Once Weekly 20/70 mg/m² (30-minute infusion): Kyprolis is administered once weekly at 20/70 mg/m², in combination with dexamethasone (Kd), or with daratumumab plus dexamethasone (DKd), or with daratumumab and hyaluronidase-fihj plus dexamethasone (DKd). The recommended starting dose is 20 mg/m² on Cycle 1, Day 1, increasing to 70 mg/m² on Day 8 if tolerated. Kyprolis is given intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle, continuing until disease progression or unacceptable toxicity. Administer dexamethasone 30 minutes to 4 hours before Kyprolis, and 1 to 3 hours before daratumumab or daratumumab and hyaluronidase-fihj.

Twice Weekly 20/56 mg/m² (30-minute infusion): Kyprolis is administered twice weekly, either as monotherapy or in combination with dexamethasone (Kd), daratumumab plus dexamethasone (DKd), daratumumab and hyaluronidase-fihj plus dexamethasone (DKd), or isatuximab plus dexamethasone (Isa-Kd).

The recommended starting dose is 20 mg/m² on Days 1 and 2 of Cycle 1, with an increase to 56 mg/m² on Day 8 if well-tolerated. Kyprolis is given intravenously as a 30-minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle, continuing until disease progression or unacceptable toxicity occurs. When used alone, administer 8 mg dexamethasone orally or intravenously 30 minutes to 4 hours before Kyprolis to minimize infusion-related reactions.

Twice Weekly 20/27 mg/m² (10-minute infusion): Kyprolis is administered twice weekly, either as monotherapy or in combination with lenalidomide and dexamethasone (KRd). The starting dose is 20 mg/m² on Days 1 and 2 of Cycle 1. If tolerated, the dose increases to 27 mg/m² on Day 8 and continues at this level. Kyprolis is given as a 10-minute intravenous infusion. For Cycles 1-12, it is administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. From Cycle 13 onward, the schedule changes to Days 1, 2, 15, and 16 of each cycle. If used alone, premedicate with 4 mg dexamethasone 30 minutes to 4 hours before each Kyprolis dose during Cycle 1, and then as needed to reduce infusion-related reactions. Continue treatment until disease progression or unacceptable toxicity.

• Treatment with Kyprolis 60 mg/30 mg/10 mg can cause serious heart problems, including heart failure and arrhythmias. Patients should be monitored for symptoms like chest pain, swelling of the legs, or shortness of breath. Those with existing heart conditions are at a higher risk and should have their heart function closely evaluated during treatment.
  
• This therapeutic drug can impact kidney function, potentially leading to acute renal failure. Regular monitoring of kidney function is necessary. Patients with pre-existing kidney issues or dehydration should be closely watched.
  
• Tumor lysis syndrome, a condition where cancer cells break down rapidly and release toxins into the bloodstream, can occur. Symptoms include high levels of potassium, phosphate, and uric acid. Hydration and monitoring of blood chemistry are crucial to manage this risk.
  
• Treatment with Carfilzomib injection may lead to lung problems, such as pulmonary fibrosis or pneumonitis, resulting in breathing difficulties. Patients should report any new or worsening cough, difficulty breathing, or chest pain to their healthcare provider.
  
• High blood pressure is a common side effect. Regular monitoring of blood pressure is essential, and hypertension should be managed according to standard guidelines to avoid complications.
  
• Carfilzomib 60 mg injection can increase the risk of blood clots in the veins, known as venous thrombosis. Patients should be vigilant for symptoms such as swelling, pain, or redness in the legs, and seek medical attention if these occur.
  
• Allergic reactions or infusion-related side effects can happen during or after administration. Symptoms might include fever, chills, or rash. Immediate medical support should be available during infusions to manage any reactions.
  
• Thrombocytopenia, characterized by low platelet counts, can occur and lead to bleeding problems. Regular blood tests are necessary to monitor platelet levels. Patients should report any unusual bleeding or bruising.
  
• Carfilzomib can harm an unborn baby. Women who are pregnant or planning to become pregnant should avoid using this medication. Effective contraception should be used during treatment.
  
• It is not known whether this therapeutic drug passes into breast milk. Because of potential risks to the infant, breastfeeding should be avoided during treatment. Women should discuss alternatives with their healthcare provider.
  

What documents are required to import KYPROLIS to India?

KYPROLIS (carfilzomib) for injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
  
• Import permit if applicable

Is KYPROLIS available in India?

KYPROLIS (carfilzomib injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input:

• On availability of Kyprolis in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from Canada, Europe, the USA, and Australia
  
• Ensuring 100% transparency.

KYPROLIS can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of KYPROLIS (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 or write us at info@indianpharmanetwork.in for Kyprolis injection price in India. 

 We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network (IPN) can source KYPROLIS (a cancer treatment medication) from across the globe and supply it to India and other countries where the medicine is not yet approved or unavailable. Through our services, we ensure that patients have worldwide access to the best available treatments.

IPN is capable of dispensing any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address directly from New Delhi, India.

What is the Generic Name for the trade name drug Kyprolis®?

Carfilzomib is the Generic Name for the trade name drug Kyprolis®.

What is the Manufacturer’s Name of Kyprolis®?

Kyprolis® is manufactured by Amgen Inc. 

Is Kyprolis® approved by the FDA?

Yes, Kyprolis® is approved by the FDA. Date of first approval: July 20, 2012.

What is the dosage and form of Kyprolis® supplied?

Kyprolis® is supplied for injection: 10 mg, 30 mg, or 60 mg lyophilized powder in single-dose vial for reconstitution for intravenous administration. 

What are the most common side effects of Kyprolis®? 

The most common side effects of Kyprolis® 

• as monotherapy are: anemia, diarrhea, fatigue, thrombocytopenia, pyrexia, dyspnea, headache, cough, and nausea.
  
• as combination therapy are: fatigue, anemia, hypertension, diarrhea, upper respiratory tract infection, dyspnea, thrombocytopenia, cough, pyrexia, and insomnia.
  

Where can I Access Kyprolis® (Carfilzomib injections) at the best price in India?

Indian Pharma Network (IPN), a certified pharmaceutical facilitator/supplier/importer and WHO-GDP certified offers Kyprolis (carfilzomib injections) in India. Although FDA-approved Carfilzomib (brand name Kyprolis) is not yet registered in India, Indian patients can purchase it upon request at the lowest price. To confirm an order for Kyprolis, a valid doctor’s prescription and, if required, an import permit must be submitted.

How much does Kyprolis® (Carfilzomib injections) cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on Carfilzomib injection cost in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Kyprolis® (Carfilzomib injections) be made available in SAARC countries? 

Apart from Gulf countries, Kyprolis® can be available in SAARC countries (Afghanistan, India, Bangladesh, Bhutan, Maldives, Nepal, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the supply of Kyprolis® (Carfilzomib) in these countries, ensuring access to this therapeutic drug through legal and reliable channels.

Is it safe to buy Kyprolis® (Carfilzomib injections) online in India?

Yes, one can buy Kyprolis (Carfilzomib) online in India at the best price from the Indian Pharma Network (IPN) if this medicinal product is not registered or is unavailable in their country. We can help facilitate the supply of Kyprolis® injections through legal channels. 

What are the storage conditions of Kyprolis®?

Store unopened vials at 2°C to 8°C (36°F to 46°F). Retain this therapeutic drug in its original package to protect it from light

In India, where has the Indian Pharma Network (IPN) imported and delivered anti-cancer medicines, including FDA-approved Carfilzomib (brand name Kyprolis)? 

For personal use, FDA-approved Carfilzomib (brand name Kyprolis) can be accessed in India through our services. We have successfully imported and delivered anti-cancer medicines to these cities: Bangalore, Kolkata, Ahmedabad, Surat, Pune, Indore, Kochi, Nagpur, Agra, Kanpur, Patna, Coimbatore, Gurugram, Delhi, Shimla, Ranchi, Amaravati, Itanagar, Dispur, Panaji, Raipur, Gandhinagar, Chandigarh, Bengaluru, Mumbai, Imphal, Thiruvananthapuram, Bhopal, Bhubaneswar, Jaipur, Shillong, Aizawl, Kohima, Gangtok, Lucknow, Dehradun, Chennai, Hyderabad, Agartala, Gairsain, Aurangabad, Cachar, Dibrugarh, Meghalaya, Barshi, Mizoram, Sikkim, Kollam, Puducherry, Punjab, Tripura, New Delhi, Mathura, Panipat, Faridabad, Alwar, Noida, Sonipat, Karnal, Ambala, Rohtak, Ghaziabad, etc.

FAQs for Generic Brand Carfilnat (Carfilzomib 60 mg injection)

What is Carfilnat (Carfilzomib 60 mg injection)?

Carfilnat is an Indian generic brand that serves as an alternative to the brand-name medicine Kyprolis. It contains the active ingredient Carfilzomib, which is used for the treatment of multiple myeloma (MM).

Is Carfilnat (Carfilzomib 60 mg) available for export from India?

Yes, we are a leading exporter of Carfilnat (generic Kyprolis) from India to various regions worldwide, including Asia, Australia, North America, South America, Central America, Eastern Europe, Western Europe, the Middle East, and Africa.

How can healthcare providers or patients access Carfilnat (Carfilzomib 60 mg) from India?

To buy Carfilzomib 60 mg injection from India, healthcare providers or patients must provide a valid prescription and comply with the import regulations of the destination country. The Indian Pharma Network (IPN) assists in navigating these requirements to ensure smooth delivery.

Where can I get Carfilnat (Carfilzomib 60 mg injection) at the best Price? 

Order Carfilzomib at the best price today. We request that you Call/WhatsApp us at +91-9310090915, dial our TOLL-FREE Number: 1800-889-1064, or write to us at info@indianpharmanetwork.in. We are fully committed to providing you with the best Carfilzomib 60 mg price from India. That is why we’ll match the cost/price of any other facilitators/suppliers/distributors in the market who require a valid medical prescription.

Is the Carfilnat (Carfilzomib 60 mg injection) available in India?

Carfilnat (Carfilzomib 60 mg injection) is a generic alternative to Kyprolis and is available in India. It is a (prescription drug, doctor-prescribed medication, or health care professional-prescribed medicine) pharmaceutical drug that can be legally dispensed against a medical prescription. A generic version of Kyprolis can be made available across the world through India’s authorized distributor network. 

Can You Send the Carfilnat (Carfilzomib 60 mg injection) to Foreign Destinations?

Buy generic Carfilzomib online at the lowest price from a leading supplier/exporter. We can assist in the delivery of Carfilzomib; the doctor-prescribed medication to Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Switzerland, the UK, Israel, Iraq, Jordan, Bahrain, Egypt, Iran, Kuwait, Qatar, Lebanon, Oman, Saudi Arabia, Syria, Turkey, UAE, Belize, Costa Rica, El Salvador, Guatemala, Italy, Czech Republic, Panama, Serbia, Slovakia, Slovenia, Ukraine, Russia, Bulgaria, Croatia, Estonia, Hungary, Kosovo, Latvia, Lithuania, Moldova, Poland, Romania, Belarus, Argentina, Brazil, Chile, Colombia, Guyana, Peru, Ecuador, Paraguay, Suriname, Uruguay, Venezuela, Canada, Mexico, US, Sri Lanka, Singapore, Japan, Indonesia, and China.

What is the procedure for buying Carfilnat (Carfilzomib 60 mg injection) from India? 

Patients can simply fill out the order form or send mail to info@indianpharmanetwork.in. Patients can also send WhatsApp messages to +91-9310090915 or dial the TOLL-FREE Number: 18008891064. We will reply ASAP with the details of the Carfilzomib 60 mg injection price and the procurement procedure.

Note:- The order will be confirmed only after the valid receipt of the prescription from the Physician.

Is it safe to buy Carfilnat (Carfilzomib 60 mg) injections online from India?

Yes, one can buy Carfilzomib 60 mg online from India-based Indian Pharma Network (IPN)  if the medicinal product is not (yet) registered or is unavailable in their respective country. We can help facilitate the supply of generic Carfilzomib through legal channels. 

What are the main export markets for Carfilnat (Carfilzomib 60 mg injection)? 

The main export markets for Carfilnat (Carfilzomib 60 mg injections) are Western Europe (Germany, Ireland, Austria, Belgium, France, Liechtenstein, Luxembourg, Monaco, Netherlands, UK, Switzerland, Andorra), Australia, the Middle East (Bahrain, Cyprus, Egypt, UAE, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Turkey, Yemen), Central America (Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama), Eastern Europe (Serbia, Slovakia, Russia, Bulgaria, Slovenia, Ukraine, Croatia, Czech Republic, Estonia, Lithuania, Moldova, Hungary, Kosovo, Latvia, Poland, Romania, Montenegro, North Macedonia, Albania, Belarus, Bosnia, Herzegovina), South America (Argentina, Bolivia, Brazil, Chile, Colombia, Guyana, Paraguay, Ecuador, Peru, Suriname, Uruguay, Venezuela), Asia (Maldives, Malaysia, Vietnam, Thailand, Singapore, Sri Lanka, Philippines, Japan, China, Indonesia, Bangladesh, Bhutan, Afghanistan), North America (Mexico,, Canada, US, Cuba, Jamaica, Haiti, and Africa.